Search / Trial NCT06615128

Assessment of Serum CD25 Level in Systemic Sclerosis Patients with or Without Interstitial Lung Disease (ILD)

Launched by ASSIUT UNIVERSITY · Sep 24, 2024

Trial Information

Current as of October 04, 2024

Not yet recruiting

Keywords

Description

Interstitial lung disease (ILD) comprises of a large group of idiopathic diffuse processes that affect the lung parenchyma. Connective tissue disease-associated lung disease (CTD-ILD) represents one of the most common causes of ILD. Along with idiopathic pulmonary fibrosis (IPF), they both represent the majority of ILDs. Since CTD-ILD typically follows a better clinical course compared to IPF, and hence therapies differ substantially between them, an accurate diagnosis is critical. Up to 30% of newly diagnosed ILD will be due to CTD. This underscores the importance of investigating all pati...

Gender

ALL

Eligibility criteria

  • 1. Inclusion criteria:
  • SSc patients fulfilled the 2013 ACR/EU LAR criteria (10). Adult age above 18 years.
  • 2. Exclusion criteria:
  • * Patients unwilling to participate in the study.
  • * Patients with other autoimmune diseases.
  • * Patients with interstitial lung disease (ILD) caused by causes other than systemic sclerosis.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0